Free Trial

MetLife (MET) Stock Forecast & Price Target

MetLife logo
$98.27 -0.20 (-0.20%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$98.32 +0.04 (+0.04%)
As of 10/9/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MetLife - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
0
Buy
12

Based on 12 Wall Street analysts who have issued ratings for MetLife in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 12 have given a buy rating for MET.

Consensus Price Target

$106.69
8.57% Upside
According to the 12 analysts' twelve-month price targets for MetLife, the average price target is $106.69. The highest price target for MET is $111.00, while the lowest price target for MET is $96.00. The average price target represents a forecasted upside of 8.57% from the current price of $98.27.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for MET and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MetLife and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MET Analyst Ratings Over Time

TypeCurrent Forecast
10/11/25 to 10/11/26
1 Month Ago
9/11/25 to 9/11/26
3 Months Ago
7/13/25 to 7/13/26
1 Year Ago
10/11/24 to 10/11/25
Strong Buy
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
12 Buy rating(s)
11 Buy rating(s)
11 Buy rating(s)
9 Buy rating(s)
Hold
0 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$106.69$102.21$98.23$95.18
Forecasted Upside8.57% Upside5.30% Upside5.58% Upside19.16% Upside
Consensus RatingBuyBuyModerate BuyModerate Buy

MET Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MET Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

MetLife Stock vs. The Competition

TypeMetLifeFinance CompaniesBroader Market
Consensus Rating Score
3.00
2.28
2.53
Consensus RatingBuyHoldModerate Buy
Predicted Upside8.57% Upside38.30% Upside19.60% Upside
News Sentiment Rating
Neutral News

See Recent MET News
Positive News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/7/2026
Mizuho logo
Mizuho
3 of 5 stars
Yaron Kinar
Yaron Kinar
Not Rated
Lower TargetOutperform$112.00 ➝ $109.00+13.45%
10/7/2026
Barclays PLC logo
Barclays
3 of 5 stars
Alex Scott
Alex Scott
3 of 5 stars
Boost TargetOverweight$97.00 ➝ $111.00+14.17%
10/6/2026
UBS Group AG logo
UBS Group
4 of 5 stars
Michael Ward
Not Rated
Boost TargetBuy$105.00 ➝ $110.00+13.44%
10/5/2026Boost TargetBuy$105.00 ➝ $110.00+14.29%
9/22/2026UpgradeNeutral ➝ Overweight$99.00 ➝ $110.00+13.71%
9/11/2026 Reiterated RatingBuy (B)
8/24/2026 Reiterated RatingMixed
8/24/2026Boost TargetOverweight$103.00 ➝ $111.00+16.15%
8/19/2026Boost TargetOverweight$101.00 ➝ $109.00+12.56%
8/11/2026Boost TargetOverweight$106.00 ➝ $108.00+11.40%
8/11/2026Boost TargetOutperform$105.00 ➝ $108.00+11.39%
7/15/2026 Set Target$103.00+11.65%
7/10/2026Boost TargetBuy$97.00 ➝ $103.00+13.02%
4/14/2026Lower TargetBuy$103.00 ➝ $99.00+29.81%
9/16/2025UpgradeStrong-Buy
1/23/2025Initiated CoverageMarket Perform$97.00+13.09%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:10 PM ET.


Should I Buy MetLife Stock? MET Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 7, 2026. Please send any questions or comments about these MetLife pros and cons to contact@marketbeat.com.

MetLife
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in MetLife, Inc.:

  • MetLife, Inc. recently announced a quarterly dividend of $0.5925 per share, which represents an annualized yield of approximately 2.4% based on the current stock price of $95.77. This payout is well-covered by earnings, with a payout ratio of 22.9%, indicating that the company retains the majority of its profits for reinvestment while still providing a reliable income stream for shareholders.
  • The company demonstrated strong financial performance in its most recent earnings report on August 5, 2026, where it reported earnings per share of $2.43, beating the consensus estimate of $2.30. This beat, combined with a 10.5% year-over-year increase in revenue to $13.52 billion, suggests that the company is effectively growing its top line and maintaining profitability despite market headwinds.
  • Analyst sentiment remains positive, with a consensus rating of "Buy" and a consensus price target of $105.08, which implies potential upside from the current trading price. Recent actions by major firms, such as TD Cowen raising its price target to $110.00 and Morgan Stanley lifting its target to $111.00, reflect confidence in the company's future earnings potential and strategic direction.
  • MetLife, Inc. has a history of consistent dividend growth, having raised its dividend annually for the last 12 consecutive years. This track record of increasing payouts provides a layer of capital preservation and income growth for long-term investors, distinguishing it from peers that may have stagnant or declining dividend policies.
  • Institutional interest in the stock has been robust, with significant new positions established by major funds such as BlackRock Inc. and Pzena Investment Management LLC in the second quarter. Additionally, Argent Capital Management LLC initiated a new stake of 121,303 shares in the third quarter, signaling that sophisticated investors are accumulating shares and viewing the current valuation as attractive.

MetLife
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in MetLife, Inc. for these reasons:

  • The stock is currently trading at $95.77, which is below its 52-week high of $100.93 and slightly below its 50-day moving average of $96.53. This positioning suggests that recent momentum has stalled or reversed, and the stock may be facing short-term resistance or a pullback from its recent highs.
  • Short interest in MetLife, Inc. has been increasing recently, with shares shorted rising to 12,285,410 as of September 15, 2026, up from 11,852,557 in the previous month. This month-over-month increase of approximately 3.65% indicates that a growing number of traders are betting against the stock, which could create downward pressure on the share price.
  • The company's balance sheet metrics show a current ratio of 0.20 and a quick ratio of 0.20, which are significantly below the standard threshold of 1.0. While common in the insurance industry due to the nature of liabilities, these low ratios indicate limited immediate liquidity to cover short-term obligations, potentially raising concerns about financial flexibility during periods of market stress.
  • MetLife, Inc. has a beta of 0.78, which is lower than the market average, but this also means the stock may underperform during strong market rallies. For investors seeking aggressive growth, the stock's defensive nature and lower volatility may result in missed opportunities compared to higher-beta financial sector peers.
  • Despite the recent dividend announcement, the average annual dividend growth over the last three years has been reported as 0.0%, suggesting that the pace of dividend increases has slowed significantly compared to historical trends. This stagnation in growth rate may disappoint income-focused investors who are looking for accelerating yield expansion.

MET Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for MetLife is $106.69, with a high forecast of $111.00 and a low forecast of $96.00.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MetLife in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MET shares.

According to analysts, MetLife's stock has a predicted upside of 8.57% based on their 12-month stock forecasts.

Over the previous 90 days, MetLife's stock had 1 upgrade by analysts.

Analysts like MetLife more than other "finance" companies. The consensus rating for MetLife is Buy while the average consensus rating for "finance" companies is Hold. Learn more on how MET compares to other companies.


MarketBeat monitors more than a dozen sources for MetLife analyst ratings, with the most recent rating issued on 10/7/2026.
From Our Partners